Mar 5, 2018
Santhera's Raxone shows no efficacy benefit in MS study - https://wp.me/p8XyML-kHw - #Benefit, #Efficacy, #MS, #Raxone, #Santheras, #Shows, #Study
seen from United States
seen from United States
seen from China
seen from United States
seen from China
seen from Sweden
seen from Switzerland
seen from Algeria
seen from Australia
seen from Greece
seen from Canada
seen from United States
seen from United States
seen from United States
seen from Poland
seen from Croatia
seen from Canada
seen from Yemen
seen from United States
seen from Ukraine
Santhera's Raxone shows no efficacy benefit in MS study - https://wp.me/p8XyML-kHw - #Benefit, #Efficacy, #MS, #Raxone, #Santheras, #Shows, #Study
Neuropatia ottica ereditaria, in commercio il Raxone
Neuropatia ottica ereditaria, in commercio il Raxone
Neuropatia ottica ereditaria Leber (Lhon), autorizzata l’immissione in commercio in Europa per il Raxone. Il farmaco, prodotto da Santhera è la prima terapia approvata per questa patologia: senza trattamento i pazienti erano destinati alla cecità nel giro di pochi mesi Liestal (Svizzera), 10/09/2015 – I pazienti europei affetti da neuropatia ottica ereditaria di Leber (LHON) hanno finalmente a…
View On WordPress